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Diabetes Mellitus is a metabolic disturbance 
characterised by hyperglycaemia and a relative 
lack, or complete absence of insulin (1). It is a 
disease, which by virtue of its complications 
may affect all organ systems in the body. 
Prevention, timely diagnosis, and treatment are 
important in patients with diabetes mellitus. 
Many of the complications associated with 
diabetes, such as nephropathy, retinopathy, 
neuropathy, cardiovascular disease, stroke, and 
death, can be delayed or prevented with 
appropriate treatment of elevated blood 
pressure, lipids, and blood glucose (2). 
Diabetes mellitus and lesser forms of 
glucose intolerance, particularly impaired 
glucose tolerance, can now be found in almost 
every population in the world and 
epidemiological evidence suggests that, without 
effective prevention and control programmes, 
diabetes will likely continue to increase globally 
(3, 4). In 2010, about 285 million people in the 
age group 20-79 were envisaged to have 
diabetes worldwide, about 70% of who live in 
developing nations. This estimate is expected to 
increase to about 438 million, by 2030 (5-8). 
Further, by 2030, the number of people with 
IGT is projected to increase to 472 million, or 
8.4% of the adult population. The debilitating 
effects of diabetes mellitus include various 
organ failures, progressive metabolic 
complications such as retinopathy, nephropathy, 
and/or neuropathy (9-11). Diabetics are 
accompanied by risk of cardiovascular, 
peripheral vascular and cerebrovascular 
diseases. Several pathogenetic processes are 
involved in the development of diabetes, 
including destruction of pancreatic β-cells that 
lead to lowered sensitivity of insulin action (12-
15). 
Estimated total annual cost associated with 
diabetes in Latin America and the Caribbean to 
be US$65.216 billion. With a prevalence of 
200,000 type 1 diabetics in India, estimated that 
the cost of treatment could be as high as US$50 
million (16). According to American Diabetes 
Association, the combined direct and indirect 
costs of diabetes in 1997 were estimated at 
US$98 billion in the United States of America. 
The estimated total direct cost of diabetes in 
Spain is over US$650 million where there were 
over 1.4 million known diabetics in 1994 (Hart 
et al., 1997). In England and Wales, the 
estimated cost of type 1 diabetes is US$1.92 
million (Gray and Fenn, 1995). Unfortunately, 
there is a dearth of similar evidence for the 
WHO African Region. The growing burden of 
diabetes and other noncommunicable diseases is 
one of the major health challenges to economic 
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developments bedeviling WHO African Region 
states. As Kirigia et al. (2009) indicate, the 
effectiveness of prevention and control of those 
illnesses rely largely on the performance of 
health systems, functions of leadership and 
governance; health workforce; medical 
products, vaccines and technologies; 
information; financing; and services delivery 
(17). 


























GCK-MODY: stable, nonprogressive elevated fasting blood 
glucose; typically does not require treatment; microvascular 
complications are rare; small rise in 2-h PG level on 
OGTT(<54 mg/dL [3mmol/L]) 
HNF1A-MODY: progressive insulin secretory defect with 
presentation in adolescence or early adulthood; lowered renal 
threshold for glucosuria; large rise in 2-h PG level on OGTT 
(>90 mg/dL [5 mmol/L]); sensitive to sulfonylureas 
HNF4A-MODY: progressive insulin secretory defect with 
presentation in adolescence or early adulthood; may have 
large birth weight and transient neonatal hypoglycemia; 
sensitive to sulfonylureas 
HNF1B-MODY: developmental renal disease (typically 














Permanent or transient: IUGR; possible developmental delay 
and seizures; responsive to sulfonylureas 
Permanent: IUGR; insulin requiring 
Transient or permanent: IUGR; rarely developmental delay; 
responsive to sulfonylureas 
 
2. Materials and Methods 
The research methodology adopted for the 
study is discussed. The methodology of the 
research includes the research design, 
description of the setting, population, sample, 
sampling technique and development of the 
tool, procedure for data collection and plan for 
data analysis. Efforts for improved criteria for 
diagnosis & classification started a decade 
before Von Mering & Minkowski's work.  
Urine Tests  
Urine tests are undertaken to analyse 
ketones bodies, glucose and proteins in the 
urine. The colorimetric reaction that occurs 
between ketones and nitroprusside (Sodium 
nitroferricyanide) is the method used for the 
rapid semiquantitive measurements of ketones 
(18). 
Maturity-Onset Diabetes of the Young 
Maturity Onset Diabetes of the Young 
(MODY), represents a rare cause of diabetes 
(1% of all cases), commonly misdiagnosed as 
Type 1 Diabetes (T1D) or Type 2 Diabetes 
(T2D). Clinical characteristics of MODY 
include age of onset before 45 years, absence of 
beta-cell autoimmunity and features of 
metabolic syndrome, sustained endogenous 
insulin production and strong family history. 
Common reasons for misdiagnosis are 
limitations in physicians' awareness and 
restrictions in performing genetic testing. In an 
attempt to improve diagnosis rates, recent 
research efforts have focused on the discovery 
of non-genetic biomarkers for prioritising 
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individuals for genetic testing, with some 
promising progress (identification of high-
sensitivity CRP, plasma glycan profile as 
HNF1A-MODY). 
Post-Transplantation Diabetes Mellitus 
Post-transplant diabetes mellitus (PTDM) is 
common after most types of solid organ 
transplantation, though the actual incidence is as 
yet unknown because of the use of different 
diagnostic criteria. PTDM is the result of 
individual risk factors as well as risk factors 
associated with the transplant itself, particularly 
immunosuppressants. Previously called New 
Onset Diabetes, in many cases inadequate 
screening for diabetes before transplant cannot 
assure that the diabetes is new after transplant. 
The most recent international consensus 
guidelines suggest diagnosis should be delayed 
until the patient is taking maintenance doses of 
immunosuppressants even if they require 
treatment in the immediate hospitalization.  
3. Results and Discussion 
Neonatal Diabetes 
We enrolled 32 patients diagnosed with 
diabetes before 6 months of age and 45 patients 
diagnosed between 6 and 12 months. We 
identified a mutation in KCNJ11 in 14 patients 
from 12 families and in INS in 7 patients from 4 
families. Three of the patients with 
an INS mutation were diagnosed with diabetes 
between 6 and 12 months of age. Finally, we 
found that two patients had an abnormality of 
chromosome 6q24 associated with transient 
neonatal diabetes mellitus. 
Maturity-Onset Diabetes of the Young 
Patients are generally asymptomatic and are 
diagnosed incidentally or as part of screening 
for diabetes, e.g. pregnancy. In pediatric 
populations, GCK-MODY was found to 
represent 40-50% of cases of asymptomatic or 
incidental hyperglycemia It is inherited in an 
autosomal dominant pattern with abnormalities 
in at least 13 genes on different chromosomes 
identified to date. The most commonly reported 
forms are GCKMODY (MODY2), HNF1A-
MODY (MODY3), and HNF4A-MODY 
(MODY1). Clinically, patients with GCK-
MODY exhibit mild, stable, fasting 
hyperglycemia and do not require anti-
hyperglycemic therapy except sometimes 
during pregnancy. Patients with HNF1A- or 
HNF4A-MODY usually respond well to low 
doses of sulfonylureas, which are considered 
first-line therapy. Mutations or deletions in 
HNF1B are associated with renal cysts and 
uterine malformations (renal cysts and diabetes 
[RCAD] syndrome). Other extremely rare forms 
of MODY have been reported to involve other 
transcription factor genes including PDX1 
(IPF1) and NEUROD1. 
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The clinical presentations of the different 
MODY subtypes differ, particularly in the 
severity and the course of the insulin secretion 
defect, the risk of microvascular complications 
of diabetes, and the defects associated with 
diabetes. Patients with MODY2 have mild, 
asymptomatic, and stable hyperglycemia that is 
present from birth. They rarely develop 
microvascular disease, and seldom require 
pharmacologic treatment of hyperglycemia. In 
patients with MODY3, severe hyperglycemia 
usually occurs after puberty, and may lead to the 
diagnosis of type 1 diabetes. Despite the 
progression of insulin defects, sensitivity to 
sulfonylureas may be retained in MODY3 
patients. Diabetic retinopathy and nephropathy 
frequently occur in patients with MODY3, 
making frequent follow-up mandatory. By 
contrast, other risk factors are not present in 
patients with MODY and the frequency of 
cardiovascular disease is not increased. The 
clinical spectrum of MODY is wider than 
initially described, and might include multi-
organ involvement in addition to diabetes. In 
patients with MODY5, due to mutations in 
hepatocyte nuclear factor-1beta, diabetes is 
associated with pancreatic atrophy, renal 
morphologic and functional abnormalities, and 
genital tract and liver test abnormalities. 
Although MODY is dominantly inherited, 
penetrance or expression of the disease may vary 
and a family history of diabetes is not always 
present. Thus, the diagnosis of MODY should be 
raised in various clinical circumstances. 
Molecular diagnosis has important consequences 
in terms of prognosis, family screening, and 
therapy. 
Post-Transplantation Diabetes Mellitus 
Currently, oGTT is considered as a golden 
standard for the diagnostics of PTDM. In the 
event of applying oGTT, the incidence of PTDM 
is significantly higher compared to the 
postprandial monitoring of glycaemia or 
applying HbA1c. oGTT allows diagnosing the 
disorder of glucose tolerance, which is a 
significant risk factor for development of PTDM 
Criteria for diagnosis follow those of the 
American Diabetes Association and the World 
Health Organization, although hemoglobin A1C 
should not be used as the only screening test at 
least until one year after transplant because of its 
insensitivity for significant glucose intolerance 
in the transplant patient and setting. Management 
of PTDM is best done in a team setting, with an 
emphasis on glycemic control, dyslipidemia, and 
hypertension, and taking into consideration 
immunosuppressant regimens and potential drug 
side effects and interactions. While PTDM has 
been associated with changes in outcomes, these 
have and may continue to improve with 
improved diabetes care in and out of the hospital, 
and other changes in post-transplant care 
The OGTT is considered the gold standard 
test for the diagnosis of PTDM. However, 
screening patients using fasting glucose and/or 
A1C can identify high-risk patients requiring 
further assessment and may reduce the number 
of overall OGTTs required.  
There is currently a lack of clinical data 
examining the use of anti-diabetes agents in the 
setting of PTDM to inform specific 
recommendations for use in this population. 
Although the use of immunosuppressive 
therapies is a major contributor to the 
development of PTDM, the risks of transplant 
rejection outweigh the risks of PTDM and the 
role of the diabetes care provider is to treat 
hyperglycemia appropriately regardless of the 
type of immunosuppression. 
Cystic Fibrosis–Related Diabetes 
CFRD mortality has significantly decreased 
over time, and the gap in mortality between 
cystic fibrosis patients with and without diabetes 
has considerably narrowed. There are limited 
clinical trial data on therapy for CFRD. The 
largest study compared three regimens: premeal 
insulin as part, repaglinide, or oral placebo in 
cystic fibrosis patients with diabetes or abnormal 
glucose tolerance. Participants all had weight 
loss in the year preceding treatment; however, in 
the insulin-treated group, this pattern was 
reversed, and patients gained 0.39 (6 0.21) BMI 
units (P 5 0.02). The repaglinide-treated group 
had initial weight gain, but this was not sustained 
by 6 months. The placebo group continued to 
lose weight. Insulin remains the most widely 
used therapy for CFRD. 
Recommendations for the clinical 
management of CFRD can be found in the ADA 
position statement “Clinical Care Guidelines for 
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Cystic Fibrosis–Related Diabetes: A Position 
Statement of the American Diabetes Association 
and a Clinical Practice Guideline of the Cystic 
Fibrosis Foundation, Endorsed by the Pediatric 
Endocrine Society”. 
4. Conclusion 
The diagnostic criterion for the diagnosis of 
diabetes mellitus has been undergoing review 
globally. The American Diabetes Association 
(ADA) and the World Health Organization 
(WHO) have always released differing 
recommendations regarding the criteria for 
diagnosis of diabetes mellitus. For instance, in 
2003 the ADA modified its recommendations 
resulting in discrepancies between its 
recommendations and those of the WHO. 
We were able to establish a genetic cause of 
diabetes in 63% of patients diagnosed with 
diabetes before 6 months of age and in 7% of 
patients diagnosed between 6 and 12 months. 
Genetic testing, which is critical for guiding 
appropriate management, should be considered 
in patients diagnosed with diabetes before 1 yr of 
age, especially if they are autoantibody negative, 
although the presence of autoantibodies does not 
rule out a monogenic cause. 
Overall, the practical implications of these 
reports for clinical practice are that the diagnosis 
of diabetes in people with classic symptoms 
should be established with a random plasma 
glucose concentration of >11.1 mmol/l, 
preferably repeated or confirmed by a raised 
fasting glucose value on a subsequent day. In 
less clear cases the diagnosis can be established 
with a fasting plasma glucose of >7.0 mmol/l, 
again repeated on a different occasion. Although 
the American Diabetes Association report was 
published as the final findings of its expert 
committee, the paper from the WHO is labelled 
as a provisional report. 
Clinicians managing patients with diabetes 
need to have an understanding of the individual 
patient’s pathophysiology that underpins their 
classification as this will significantly help in the 
clinical management and risk stratification for 
diabetes chronic vascular complications. 
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